Prognostic factors in Waldenstrom's macroglobulinemia: Description of the complications during the evolution - Preliminary results on 101 patients

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 216-219

  Stalnikiewicz, Laure ^a,b,c,d,e   Carrotte Lefebvre, Isabelle ^a,b,c,d,e   Detourmignies, Laurence ^a,b,c,d,e   Rose, Christian ^a,b,c,d,e   Cazin, Bruno ^a,b,c,d,e   Leblond, Véronique ^a,b,c,d,e   Morel, Pierre ^a,b,c,d,e  

^a Centre Hospitalier de LENS   (France)

^b CENTRE HOSPITALIER DE ROUBAIX   (France)

^c Centre Hospitalier Saint Vincent de Paul   (France)

^d Service des Maladies du Sang   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISOLONE; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CYTOPENIA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SECOND CANCER; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0242684425     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50076     Document Type: Article

References (17)

1. Waldenström JG: Macroglobulinemia: A review. Haematologica 71:437-440, 1986
2. Dimopoulos MA, Alexanian R: Waldenström macroglobulinemia. Blood 83:1452-1459, 1994
3. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenström's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-225, 2000
4. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
5. Gobbi PG, Bettini R, Montecucco C, et al: Study of prognosis in Waldenström's macroglobulinemia A proposal for a simple binary classification with clinical and investigational utility. Blood 83:2939-2945, 1994
6. Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenström's macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858, 2000
7. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41-48, 2001
8. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Waldenström macroglobulinemia: A report of 167 cases. J Clin Oncol 11:1553-1558, 1993
9. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al: Waldenstrom's macroglobulinemia: Clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 80:722-727, 2001
10. Garcia-Sanz R, Montoto S, Torrequebrada A, et al: Waldenstrom macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol 115:575-582, 2001
11. Kyle RA, Greipp PR, Gertz MA, et al: Waldenström's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000
12. Leblond V, Levy V, Maloisel F, et al: The French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644, 2001
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
15. Tai BC, Machin D, White I, et al: Competing risks analysis of patients with osteosarcoma: A comparison of four different approaches. Stat Med 20:661-684, 2001
16. Landmark JR, Cain KC, Geller RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
17. Schop RF, Jalal SM, Van Wier SA, et al: Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 132:55-60, 2002